Your session is about to expire
← Back to Search
IO102-IO103 + Pembrolizumab for Advanced Melanoma
Study Summary
This trial is investigating the safety and efficacy of IO102-IO103 in combination with pembrolizumab as first-line treatment for patients with previously untreated unresectable or metastatic (advanced) melanoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have active brain metastases or my brain metastases are stable.My melanoma is at an advanced stage and cannot be removed with surgery.I have at least one tumor that can be measured.I had targeted or immune therapy over 6 months ago and didn't relapse during or within 6 months after treatment.I can provide a recent biopsy sample and blood for testing.My melanoma has a BRAFV600 mutation and I haven't received treatment for it yet.My cancer has a BRAFV600 mutation and is worsening quickly after standard treatment.I have not received any treatment for my advanced melanoma.I had radiotherapy over 2 weeks ago and have recovered from side effects.
- Group 1: IO102-IO103 + pembrolizumab
- Group 2: pembrolizumab
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there any precedent for this combination of drugs?
"At this moment, there are 1000 ongoing clinical trials for IO102-IO103 with 122 of them being in Phase 3. However, many of the trials for IO102-IO103 are based in Houston, Texas, there are 35962 locations running studies for IO102-IO103."
Has the FDA cleared IO102-IO103 for prescription use?
"There is already some efficacy data available for IO102-IO103, as well as multiple rounds of data attesting to its safety. Consequently, we have given it a score of 3."
For what therapeutic purposes is IO102-IO103 often prescribed?
"IO102-IO103 has demonstrated efficacy in the treatment of malignant neoplasms, unresectable melanoma, and microsatellite instability high."
Share this study with friends
Copy Link
Messenger